Colleen F. Hanrahan - Concepedia

Author

Colleen F. Hanrahan

Also Known As

C F Hanrahan, C Hanrahan, C. F. Hanrahan, C. Hanrahan, Clouse, Kate, Colleen F Hanrahan, Colleen F. Hanrahan, Colleen Hanrahan, Hanrahan, Colleen F., Koornhof, Hendrik

Publications

5.1K

Citations

H-Index

Concepts

All Affiliations

Johns Hopkins University Perinatal HIV Research Unit University of the Witwatersrand University of North Carolina at Chapel Hill Johns Hopkins Medicine

About

Colleen F. Hanrahan is an author at Johns Hopkins University specializing in medicine, public health, and tuberculosis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	14	2.4K
2	Public Health	8	8	306
3	Health Sciences	1	1	112
4	Natural Sciences	1	1	62
5	Biochemistry	1	1	62

Colleen F. Hanrahan

Publications

4.7K

Citations

H-Index

Page 1

	Year	Citations
Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Hua Zhong, Kelly A. Chiles, David M. Feldser, PubMed Cancer BiologyTumor BiologyTumor AngiogenesisSignaling PathwayCell Regulation	2000	1.5K
Levels of Hypoxia-Inducible Factor-1 During Breast Carcinogenesis Reinhard Bos, Haining Zhong, Colleen F. Hanrahan, JNCI Journal of the National Cancer Institute	2001	588
Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines Marina Protopopova, Colleen F. Hanrahan, B. V. Nikonenko, Journal of Antimicrobial Chemotherapy	2005	371
Pharmacodynamics and pharmacokinetics of SQ109, a new diamine‐based antitubercular drug Lee Jia, Joseph E. Tomaszewski, Colleen F. Hanrahan, British Journal of Pharmacology Pharmaceutical ScienceHigh-throughput Combinatorial ScreeningTuberculosis PreventionImmunologyPharmacotherapy	2004	235
Angiogenesis and prostate cancer: identification of a molecular progression switch. Wendy J. Huss, Colleen F. Hanrahan, Roberto Barrios, PubMed PathologyCancer BiologyTumor BiologyAngiogenesisOncology	2001	234
Body mass index and risk of tuberculosis and death Colleen F. Hanrahan, Jonathan E. Golub, Lerato Mohapi, AIDS	2010	167
Determinants of PCR performance (Xpert MTB/RIF), including bacterial load and inhibition, for TB diagnosis using specimens from different body compartments Grant Theron, Jonny Peter, Greg Calligaro, Scientific Reports	2014	120
Identification of New Diamine Scaffolds with Activity against <i>Mycobacterium tuberculosis</i> Elena Bogatcheva, Colleen F. Hanrahan, B. V. Nikonenko, Journal of Medicinal Chemistry Antimicrobial ChemotherapyDiverse 5000-Compound LibraryDrug ResistanceMedicinal ChemistryNew Diamine Scaffolds	2006	112
Time to Treatment and Patient Outcomes among TB Suspects Screened by a Single Point-of-Care Xpert MTB/RIF at a Primary Care Clinic in Johannesburg, South Africa Colleen F. Hanrahan, Katerina Selibas, Christopher B. Deery, PLoS ONE	2013	85
Rapamycin induces Smad activity in prostate cancer cell lines Henk G. van der Poel, Colleen F. Hanrahan, Hua Zhong, Urological Research UrologyTumor SuppressorProstatic Disease	2003	70

Page 1